MOR, Marco
 Distribuzione geografica
Continente #
EU - Europa 6.520
NA - Nord America 6.214
AS - Asia 2.499
AF - Africa 92
SA - Sud America 11
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 3
Totale 15.346
Nazione #
US - Stati Uniti d'America 6.123
CN - Cina 1.862
FI - Finlandia 1.305
IE - Irlanda 1.281
IT - Italia 1.143
SE - Svezia 1.109
UA - Ucraina 625
DE - Germania 572
SG - Singapore 252
TR - Turchia 244
AT - Austria 145
GB - Regno Unito 108
CI - Costa d'Avorio 89
CA - Canada 87
IN - India 74
BE - Belgio 67
FR - Francia 56
CZ - Repubblica Ceca 31
NL - Olanda 22
VN - Vietnam 20
ES - Italia 18
HK - Hong Kong 18
JP - Giappone 9
CL - Cile 7
EU - Europa 7
RO - Romania 7
IR - Iran 6
HR - Croazia 5
PL - Polonia 5
BR - Brasile 4
KR - Corea 4
LU - Lussemburgo 4
RU - Federazione Russa 4
TH - Thailandia 4
EG - Egitto 3
HU - Ungheria 3
NO - Norvegia 3
PA - Panama 3
LT - Lituania 2
NZ - Nuova Zelanda 2
AU - Australia 1
BG - Bulgaria 1
EE - Estonia 1
ID - Indonesia 1
IL - Israele 1
IQ - Iraq 1
JO - Giordania 1
LI - Liechtenstein 1
MX - Messico 1
MY - Malesia 1
PK - Pakistan 1
PT - Portogallo 1
RS - Serbia 1
Totale 15.346
Città #
Chandler 1.285
Dublin 1.272
Jacksonville 752
Dearborn 456
Ann Arbor 440
Parma 416
Ashburn 413
Beijing 389
Nanjing 315
Princeton 248
Izmir 233
Shanghai 204
Wilmington 189
San Mateo 162
New York 151
Vienna 136
Singapore 134
Bremen 113
Helsinki 108
Shenyang 107
Boardman 95
Nanchang 92
Abidjan 89
Hebei 86
Jinan 84
Kunming 80
Toronto 80
Hefei 70
Los Angeles 65
Des Moines 58
Milan 58
Brussels 57
Seattle 55
Düsseldorf 52
Jiaxing 49
Changsha 48
Bologna 44
Pune 41
Guangzhou 38
Woodbridge 38
Tianjin 37
Fremont 33
Norwalk 30
Brescia 26
Grafing 24
Zhengzhou 24
Brno 22
Houston 22
Fuzhou 20
Hangzhou 20
Modena 20
Dong Ket 18
Auburn Hills 15
Hong Kong 12
Palermo 12
Borås 11
Chicago 11
Lanzhou 11
London 11
Ningbo 11
Chengdu 10
Fairfield 10
Haikou 10
Naples 10
Piacenza 10
Madrid 9
Paris 9
Taizhou 9
Ankara 8
Ardea 8
Munich 8
Redmond 8
Weihai 8
Delhi 7
Leuven 7
Neviano degli Arduini 7
Prata Di Pordenone 7
Tokyo 7
Xian 7
Ascoli Piceno 6
Chongqing 6
Follonica 6
Montegaldella 6
Mordano 6
Reggio Nell'emilia 6
Tappahannock 6
Wenzhou 6
Wuhan 6
Atlanta 5
Augusta 5
Belluno 5
Canneto sull'Oglio 5
Collecchio 5
Falls Church 5
Fiorano Modenese 5
Huizen 5
Redwood City 5
Reggio Emilia 5
Rome 5
Segrate 5
Totale 9.465
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 200
UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. 132
Benzisothiazolinone Derivatives as Potent Allosteric Monoacylglycerol Lipase Inhibitors That Functionally Mimic Sulfenylation of Regulatory Cysteines 132
Analysis of illicit dietary supplements sold in the Italian market: Identification of a sildenafil thioderivative as adulterant using UPLC-TOF/MS and GC/MS. 119
Analysis of Structure-Activity Relationships for MT2 Selective Antagonists by Melatonin MT1 and MT2 Receptor Models 115
2-Aminobenzimidazoles as new potent H3-antagonists 112
Dibasic biphenyl H(3) receptor antagonists: Steric tolerance for a lipophilic side chain. 105
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. 101
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 101
Application of 3D-QSAR in the Rational Design of Receptor Ligands and Enzyme Inhibitors 99
Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction 98
Amino acid derivatives as palmitoylethanolamide prodrugs: Synthesis, in vitro metabolism and in vivo plasma profile in rats 98
Drug-gut microbiota metabolic interactions: the case of UniPR1331, selective antagonist of the Eph-ephrin system, in mice 98
Antidepressant-like activity and cardioprotective effects of fatty acid amide hydrolase inhibitor URB694 in socially stressed Wistar Kyoto rats 98
Metabolic Soft Spot and Pharmacokinetics: Functionalization of C-3 Position of an Eph–Ephrin Antagonist Featuring a Bile Acid Core as an Effective Strategy to Obtain Oral Bioavailability in Mice 98
2-N-Acylaminoalkylindoles: Design and Quantitative Structure-Activity Relationship Studies Leading to MT2-Selective Melatonin Antagonists 94
Antidepressant-like effects of pharmacological inhibition of FAAH activity in socially isolated female rats 93
Structure–Activity Relationships and Mechanism of Action of Eph–ephrin Antagonists: Interaction of Cholanic Acid with the EphA2 Receptor 92
Synthesis and 3D-QSAR Analysis of H3 Receptor Antagonists Containing a Neutral Heterocyclic Polar Group 90
QSAR study of 2-aminobenzimidazole derivatives as H3 antagonists 90
5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity 89
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 88
Cardioprotective effects of fatty acid amide hydrolase inhibitor URB694, in a rodent model of trait anxiety 87
Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability 86
Design and structure-activity relationship of amino acid derivatives of lithocholic acid as novel EphA2 antagonists 86
Application of a SCC-DFTB QM/MM approach to the investigation of the catalytic mechanism of fatty acid amide hydrolase. 86
Chiral Recognition of Flexible Melatonin Receptor Ligands Induced by Conformational Equilibria 85
N-Acylethanolamine Acid Amidase (NAAA): Structure, Function, and Inhibition 85
Aminobenzimidazoles as new potent H3-antagonists 85
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line 85
The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment 85
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 84
Synthesis and biological assays of new H3-antagonists with imidazole and imidazoline polar groups 84
Free-Energy Simulations Support a Lipophilic Binding Route for Melatonin Receptors 83
A New Potent and Selective Histamine H3-Receptor Antagonist, 4(5)-{2-[4(5)-cyclohexylimidazol-2-ylthio]ethyl}imidazole 83
Validation of a histamine H3 receptor model through structure–activity relationships for classical H3 antagonists 82
Antiproliferative and proapototic effects of a new combi-molecule on non small cell lung cancer cell lines 82
Alchilammidi tricicliche: ligandi selettivi dei recettori melatoninergici MT1 e MT2 81
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 80
4-(1,2-benzisothiazol-3-)alkanoic and phenylalkanoic acids: synthesis and anti-inflammatory, analgesic and antipyretic activities 79
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 79
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. 79
Synthesis, Structural Elucidation, and Biological Evaluation of NSC12, an Orally Available Fibroblast Growth Factor (FGF) Ligand Trap for the Treatment of FGF-Dependent Lung Tumors 79
A critical cysteine residue in monoacylglycerol lipase is targeted by a new class of isothiazolinone-based enzyme inhibitors. 78
Toward the Definition of Stereochemical Requirements for MT(2)-Selective Antagonists and Partial Agonists by Studying 4-Phenyl-2-propionamidotetralin Derivatives. 77
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin protein-protein interaction 77
Dibasic non-imidazole histamine H3 receptor antagonists with a rigid byphenyl scaffold. 76
Plasma concentration and brain penetration of the H3-receptor antagonist Thioperamide in rats 76
Cyclohexylcarbamic Acid 3'- or 4'-Substituted Biphenyl-3-yl Esters of as Fatty Acid Amide Hydrolase Inhibitors: Synthesis, Quantitative Structure-Activity Relationships and Molecular Modelling Studies 75
HPLC detection ofthioperamide from biological samples and its determination in rat blood and brainafter systemic administration 75
Chapter 9: Natural and Synthetic Agents That Target Intracellular Monoacylglycerol Lipase (MGL) Activity 75
Clinical perspective for irreversible tyrosine kinase inhibitors in cancer 75
A catalytic mechanism for cysteine N-terminal nucleophile hydrolases, as revealed by free energy simulations 74
Tricyclic Alkylamides as Melatonin Receptor Ligands with Antagonist or Inverse Agonist Activity 74
ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS 73
Antioxidant and cytoprotective activity of indole derivatives related to melatonin 73
QM/MM modelling of oleamide hydrolysis in fatty acid amide hydrolase (FAAH) reveals a new mechanism of nucleophile activation 73
Development of 3-oxo-cholenic derivatives as Eph antagonists able to block in vitro angiogenesis 73
Pushing the Boundaries of Vinylogous Reactivity: Catalytic Enantioselective Mukaiyama Aldol Reactions of Highly Unsaturated 2-Silyloxyindoles 73
N-(Anilinoethyl)amides: design and synthesis of metabolically stable, selective melatonin receptor ligands 72
Synthesis, biological activity, QSAR and QSPR study of 2/aminobenzimidazole derivatives as potent H3-antagonists 72
Synthesis and structure-activity relationships for biphenyl H3 receptor antagonists with moderate anti-cholinesterase activity. 72
Development of a GPCR model for SAR interpretation of classical and new H3 antagonists 72
5-benzylidene-hydantoin UPR 1024 acts as EGFR inhibitor and induces DNA damage in A549 NSCLC cell line 72
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 72
Chiral NMR discrimination of the diastereoisomeric salts of the H(3)-antagonist 2-[3-(1H-imidazol-4-ylmethyl)piperidin-1-yl]-1H-benzimidazole. 71
Modulation of Anxiety Through Blockade of Anandamide Hydrolysis 71
Design and structure-activity relationships of amino acid derivatives of lithocholic acid as novel EphA2 receptor antagonists. 71
Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach 70
Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists 70
A second generation of carbamate-based fatty acid amide hydrolase inhibitors with improved activity in vivo 70
N-(2-Oxo-3-oxetanyl)carbamic Acid Esters as N-Acylethanolamine Acid Amidase Inhibitors: Synthesis, Structure–Activity and Structure–Property Relationships. 70
Combining pharmacology, target hopping and computational medicinal chemistry to discover novel scaffold targeting EPH-ephrin interaction. 70
New strategies to overcome resistance to EGFR tyrosine kinase inhibitors in non small cell lung cancer 69
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 69
Experimental and Theoretical Analysis of the Interaction of (±)-cis-Ketoconazole with b-Cyclodextrin in the presence of (+)-L-Tartaric Acid 68
Heteroarylaminoethyl and heteroarylthioethylimidazoles. Synthesis and H3-receptor affinity 68
Predicting the reactivity of nitrile-carrying compounds with cysteine: a combined computational and experimental study. 68
Indole-based analogs of melatonin: in vitro antioxidant and cytoprotective activities 67
Synthesis, Pharmacological Evaluation and Structure-Activity Relationships of Benzopyran Derivatives with Potent SERM Activity 67
MT2 selective melatonin receptor antagonists: design and structure-activity relationships 67
Irreversible EGFR inhibitor compounds with antiproliferative activity 67
L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC 67
Biological studies on 1,2-benzisothiazole derivatives. V. Antimicrobial properties of N-alkanoic, N-arylalkanoic and N-aryloxyalkanoic derivatives of 1,2-benzisothiazolin-3-one: QSAR study and genotoxicity evaluation 67
5-benzylidene-hydantoins as new inhibitors of cell proliferation 67
Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 7. Synthesis and Pharmacological Evaluation of 4-Quinolone-3-carboxamides and 4-Hydroxy-2-quinolone-3-carboxamides as High Affinity Cannabinoid Receptor 2 (CB2R) Ligands with Improved Aqueous Solubility 67
N-Acylethanolamine Acid Amidase (NAAA): Mechanism of Palmitoylethanolamide Hydrolysis Revealed by Mechanistic Simulations 67
Structure-Property Relationships on Histamine H3-Antagonists: Binding of Phenyl-substituted Alkylthioimidazole Derivatives to Rat Plasma Proteins 66
Sviluppo e caratterizzazione farmacologica di un nuovo potente e selettivo H3-bloccante istaminico non-tioureico 66
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer 66
270 Discovery, development and optimization of low molecular weight EPH–ephrin protein–protein inhibitors 66
Discovery and development of low molecular weight Eph-ephrin protein-protein inhbi-tors endowed with antiangiogenic activity 66
Development and validation of a LC-MS method with electrospray ionization for the determination of the imidazole H(3) antagonist ROS203 in rat plasma. 66
Imidazole H3-antagonists: Relationship between Structure and Ex-vivo binding to Rat Brain H3-Receptors 66
Tetrahydroquinoline Ring as a Versatile Bioisostere of Tetralin for Melatonin Receptor Ligands 66
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion 65
Atropisomerism and Conformational Equilibria: Impact on PI3Kδ Inhibition of 2-((6-Amino-9H-purin-9-yl)methyl)-5-methyl-3-(o-tolyl)quinazolin-4(3H)-one (IC87114) and Its Conformationally Restricted Analogs 65
Relationship between structure and ex-vivo binding of imidazole H3 antagonists to rat brain H3 receptors 64
Ligands for the histamine H3-receptor: new potent antagonists of the 2-thioimidazole type 64
Catalytic, Asymmetric Hypervinylogous Mukaiyama Aldol Reactions of Extended Furan-Based Silyl Enolates 64
Totale 8.074
Categoria #
all - tutte 55.895
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.895


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.997 508 450 178 43 250 345 391 63 314 172 89 194
2020/20211.559 19 179 155 61 192 51 206 40 341 45 213 57
2021/20221.311 24 37 14 121 85 40 149 175 91 102 90 383
2022/20235.095 551 503 311 392 486 607 46 313 1.575 60 188 63
2023/20241.980 109 148 56 68 145 457 166 159 78 124 201 269
2024/2025141 141 0 0 0 0 0 0 0 0 0 0 0
Totale 15.687